news
New colon organoids better resemble both healthy and diseased colons
Researchers have developed organoids with naturally occurring early-stage immune cells, which could lead to effective personalised treatment.
List view / Grid view
Personalised Medicine
news
New technique to extract and analyse extracellular vesicles
Cellulose nanofiber sheets enable analysis of EVs, and miRNAs within them, offering potential for cancer treatment and personalised medicine.
news
Protein found to control breast cancer metastasis
Scientists have discovered the motor protein dynein commands movement of cancer cells in soft tissue models, offering new clinical targets.
whitepaper
ebook: Maximizing preclinical confidence in target efficacy and safety
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
webinar
Turning Plans into Reality: Real Examples of Custom Automation Projects
24 August 2023 | By Bio-Rad Laboratories Inc.
Watch our industry experts to learn about the tangible benefits and best practice of custom flow cytometry automation projects. You’ll discover how to reduce your challenges implementing tailored automation, controlling the quality of the data produced and improving the reliability of your data acquisition.
article
HPV-associated head and neck cancers identified
Human papillomavirus (HPV)-associated head and neck cancers, specifically head and neck squamous cell carcinoma (HNSCC), are on the rise worldwide. Yet, the factors contributing to these tumours and their varying responses to treatment remain poorly understood.
article
Precision medicine: exploring the impact of DNA Testing
The potential of precision medicine requires a small shift in perspective, Patrick Short, CEO and co-founder of Sano Genetics, explains in this Q&A.
article
Navigating the challenges and opportunities of AI in drug development and personalised medicine
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
news
Revolutionary way to measure proteins aids precision medicine advancements
Using a nanofluidic aptamer nanoarray to measure biomolecules including proteins, Japanese researchers are attempting to bridge the gap for precision medicine
webinar
Innovations in organoid modelling for disease modelling and cell therapy
14 June 2023 | By Sartorius
Watch our virtual panel, where you'll uncover the game-changing advantages of organoids over traditional 2D cultures. Our experts will explore the immense potential of organoids in oncology and immuno-oncology research.
article
Challenges and promises of personalised precision medicine
Drug Target Review’s Taylor Mixides exclusively interviews Neil Thomas, Partner and Head of Healthcare and Life Sciences for EMEA at Infosys Consulting, on personalised precision medicine, its advances, challenges and the future.
news
Inflammation ‘brake’ gene may impact kidney disease outcomes
Australian researchers uncover a gene that controls inflammation in kidney disease, which could pave the way for more precise disease diagnostics and personalised treatments.
article
2023 drug discovery forecast: emerging trends and disruptors revolutionising the industry
With advancements in artificial intelligence, precision medicine and gene editing, the field of drug discovery is undergoing a rapid transformation. In this article, Drug Target Review’s Izzy Wood gets the insider knowledge from industry leaders at SLAS 2023, who are experiencing these changes first hand.
news
Assessing the accuracy of model arteries
Japanese scientists have tested the material used to build models of arteries, revealing their suitability for use in medical education and surgical planning.
news
Researchers develop organoid models to study non-alcoholic fatty liver disease
The team used these models to show drug responses and established a CRISPR-screening platform to identify potential therapeutic targets for non-alcoholic fatty liver disease.
